AYMAN OMAR, MD, PhD, MSc (Oxon), LMCC, DABPN Neurologist...
Transcript of AYMAN OMAR, MD, PhD, MSc (Oxon), LMCC, DABPN Neurologist...
Page 1 of 31
AYMAN OMAR, MD, PhD, MSc (Oxon), LMCC, DABPN
Neurologist / Neurological Oncologist / Neuroscientist / Specialist in
Endovascular Neurosurgery Email:[email protected]
https://www.linkedin.com/in/aymanomarmd
www.BrainTumorExperts.org Cell: 224-420-2453
CURRENT TITLE:
May 2013 – Present President and Founder Neurology and NeuroOncology Consultant, LLC Providing specialized consulting services in
Neurology and Neurological Oncology
May 2013 - Present Locum Attending Neurologist and NeuroOncologist CompHealth, OnyxMD and Vista Staffing Solutions
Practicing in 4 states: IL, IN, MO and KS
EDUCATION
Premedical
01/1985 - 01/1986 General Certificate of Education (GCE 6As and 2Bs) University of London, School Examinations Board
London, UK (Through the British Council in Stockholm and Cairo)
10/1982 - 7/1985 International Baccalaureate (IB) (completed 3 year program of study) Norra Real Gymnasium - High School
Stockholm, SWEDEN
Page 2 of 31
Medical School
10/1986 - 12/1992 Doctor of Medicine (MBChB) (Awarded Medical Degree with
Honors
University of Cairo Cairo, EGYPT
Graduate Studies
10/2014 - 10/2015 Master of Science (MSc) in Endovascular Neurosurgery University of Oxford Nuffield Department of Surgery
St. Peter’s College Oxford, UK
09/1999 - 10/2002 Doctorate in Philosophy (PhD) (GPA: 3.83/4.0)
Neuroscience / Cellular and Molecular Medicine University of Ottawa
Faculty of Graduate and Postdoctoral Studies (FGPS) Ottawa, CANADA
01/1998 - 09/1999 Master of Science (MSc), Anatomy and Neurobiology
(Recommended to Ph.D. Program due to exceptional progress without completion of a Masters thesis) University of Ottawa
Dept. of Cellular and Molecular Medicine Ottawa, CANADA
06/1995 - 10/1995 Program of Study, Lab Technology and Electron Microscopy
Seneca College of Applied Arts and Technology Toronto, ON, CANADA
Page 3 of 31
CLINICAL TRAINING
Internships
6/1/1993 - 10/31/1993 House Officer (Rotational Intern) 12/1/1995 - 6/30/1996 Cairo University Teaching Hospitals Received intensive 12 months training in the following areas:
Neurosurgery and Neuro-traumatology: 8 wks; General and Vascular Surgery: 8 wks; Orthopedics: 4 wks; Emergency Surgery:
4 wks; OB/GYN: 8 wks; General Pediatrics and neonatal intensive care: 8 wks; General Internal Medicine: 8 wks.
07/2002 – 6/2003 Intern in Internal Medicine
University of Missouri – Columbia Harry S. Truman Memorial Veterans Administration Hospital Columbia, MO, USA
Residency and Chief Residency 07/2005 - 7/2006 Chief Resident in Neurology
University of Missouri - Columbia Harry S. Truman Memorial Veterans Administration Hospital
Columbia, MO, USA
07/2003 - 7/2005 Resident in Neurology University of Missouri - Columbia, MO, USA
Harry S. Truman Memorial Veterans Administration Hospital, Columbia, MO, USA
My responsibilities included admitting, evaluating and managing patients on Neurology inpatient, consult, acute stroke call, EMG,
EEG, sleep studies etc. Additional privileges at the Rusk Rehab as well as Columbia Regional Hospital.
Clinical and Research Fellowships
10/2014 - 10/2015 Fellow (Specialist Registrar) in Endovascular Neurosurgery
University of Oxford Hospitals NHS Trust John Radcliffe Hospital
Oxford, UK
Page 4 of 31
7/2014 - 9/2014 Mini-fellowship / Course (3 months) Cleveland Clinic Foundation
Department of Neurology, Epilepsy Center Cleveland, OH
Training in Epilepsy, epilepsy surgery, Electroencephalography both adult and pediatric, invasive testing including depth electrodes
and subdural grid interpretation, Evoked Potential interpretation, Polysomnography, Intraoperative monitoring and clinical neurophysiological techniques
7/2006 – 7/2008 Clinical Fellow and Research Fellow in Neurological Oncology University of Toronto Princess Margaret Hospital, Pencer Brain Tumor Center
Department of Medicine, Division of Hematology and Oncology Toronto, ON, CANADA
07/2000 – 7/2002 Canadian Institutes of Health Research (CIHR/MRC) Fellow
Canadian Institutes of Health Research Ottawa Health Research Institute, Ottawa Hospital
University of Ottawa Division of Neurosciences
WORK EXPERIENCE:
7/29/2013 - 7/31/2015 Adjunct Assistant Professor of Neurology Southern Illinois University School of Medicine State of Illinois
Springfield, IL
6/3/2013 - Present Internal Medicine Locum Physician Kindred Hospital
Peoria, IL Manage long term acute care (LTAC) patients including critical
care issues and General Internal Medicine
Page 5 of 31
6/7/2010 – 7/29/2013 Program Director and Division Chief of Neurological Oncology Assistant Professor of Clinical Neurology
Southern Illinois University School of Medicine State of Illinois
Springfield, IL Built the first NeuroOncology Program in Central and Southern Illinois
6/7/2010 – 7/29/2013 Staff Attending Physician, Dept. of Neurology St. John’s Hospital Sisters Network Springfield, IL
6/7/2010 – 7/29/2013 Staff Attending Physician, Dept. of Neurology Memorial Medical Center Springfield, IL
6/7/2010 – 7/29/2013 Director, Division of NeuroOncology Simmons Cancer Institute (SIU School of Medicine) Springfield, IL
7/1/2009 - 3/31/2010 Clinical Assistant Professor of Neurology
University of Chicago, Pritzker School of Medicine Biological Sciences Division Chicago, IL
8/1/2008 - 3/31/2010 Attending Neurologist and NeuroOncologist NorthShore University HealthSystem
Evanston, IL
01/1997 - 06/1997 Internal Medicine Physician (Private Practice) Nile Badrawi Hospital
Cairo, Egypt My responsibilities included management of inpatients as well as
outpatients (including neurology, cardiology, pulmonology, oncology, gastroenterology, and a wide variety of general internal
medicine cases). In addition, I was responsible for the monitoring of 30 regular hemodialysis patients as well as post-op care of renal transplant recipients. The department received 30-50 patients daily
including those admitted through HMO’s covering the Middle East region, (Middle East Medicare Plan).
Page 6 of 31
07/1996 - 10/1996 Internal Medicine Physician (Private Practice) Al-Salam Hospital
Cairo, Egypt
My responsibilities included management of patients admitted to the ICU and CCU in addition to the Dialysis Unit, where I monitored patients and performed preoperative workup and
postoperative care of renal transplant recipients.
LICENSURE:
1. United Kingdom, General Medical Council, Full Registration with a license to
practice, granted January 31, 2015, GMC # 7480950
2. State of Missouri, Permanent Physician and Surgeon License, issued October 2013
3. State of Kansas, Permanent Physician and Surgeon License, issued March 2014
4. State of Illinois, Physician and Surgeon Permanent License, 2008
4. State of Indiana, Permanent Physician License, License #01062696A, 2006
5. Canada, Province of Ontario, Member, College of Physicians and Surgeons of Ontario,
License # 85030, 2006 (Expired)
6. Egypt National Medical License, General Medical License (Full Registration), Ministry
of Health, Egypt, 1996 (Permanent)
7. State of Missouri Temporary License, Physician and Surgeon Temporary License for
training, USA, 2002 - 2006 (Expired)
Page 7 of 31
CERTIFICATIONS:
1. The international English language testing system (IELTS) (University of Cambridge
English Language Exam) Scored Band 8 out of 9: First attempt November 2014 2. Radiation Protection and Radiation Physics course (4 months) - Completed January 2015.
Course accredited by the UK Royal Society of Radiologists
3. Good Clinical Practice Training: John Radcliffe Hospital, Oxford, UK, May 2015 4. Oxford Aneurysm Treatment School course: Passed 2015
5. European Course on Minimally Invasive Neurological Therapy (ECMINT1): Passed
6. European Course on Minimally Invasive Neurological Therapy (ECMINT1.2): Passed June
24-27, 2015
7. Certified, National Institutes of Health Stroke Scale, National Stroke Association, 10/13-
10/15 8. Board Certified, American Board of Psychiatry and Neurology, Jan. 14, 2011
9. Licentiate of the Medical Council of Canada (LMCC), 2006
10. Medical Council of Canada Qualifying Examination, Part II (MCCQE II), 2005 11. Medical Council of Canada Qualifying Examination, Part I (MCCQE I), May, 2000
12. Medical Council of Canada Evaluating Examination (MCCEE), September, 1999
13. Certified by the Educational Commission for Foreign Medical Graduates (ECFMG),USA (1998)
14. United States Medical Licensing Examination (USMLE), Step 3, 2008
15. United States Medical Licensing Examination (USMLE), Step 2CS, 2008 16. United States Medical Licensing Examination (USMLE), Step 2, March, 1996
17. United States Medical Licensing Examination (USMLE), Step 1, June, 1995
18. Cert. Basic Cardiac Life Support (BCLS) Provider, St. John Ambulance, Ottawa, 1999, Re-
certified in 2002 and 2004 and February 6, 2014 and UK BLS and PLS Certified in June
2015.
19. Cert. Advanced Cardiac Life Support (ACLS) Provider, American Heart Association, 1999, Re-certified in 2002, 2004 and April 13, 2014
Page 8 of 31
20. Cert. Advanced Trauma Life Support (ATLS) Provider, American College of Surgeons,
April, 2000
21. Test of English as a Foreign Language (TOEFL); score: 290 (CBT; 99th percentile) 22. Test of Spoken English (TSE), February 2000; score: 60 (99th percentile)
23. Completed course on Minimizing Healthcare Errors with Crew Training International
designed for healthcare professionals using fighter jet pilot standards. 24. Completed New Formulations for Anti-Epileptic Drugs, AB Comm. Inc., May, 2004
25. Certified in Institutional Review Board (IRB) policies and procedures for conducting clinical
research (12/31/05) 26. Certified in Health Sciences Health Insurance Portability and Accountability Act (HIPAA)
guidelines (12/31/2005)
27. National Institutes of Health (NIH), National Cancer Institute (NCI) Investigator number assigned since 2008
28. Successfully completed the Collaborative Institutional Training Initiative (CITI), 2011. This is an international course designed to educate researchers on international, local and FDA
regulations designed for the appropriate and ethical conduct of research involving human subjects. Course includes 28 modules and additional modules for IRB members (completed all modules).
29. Ethics Training for University Employees (Online Course), 2011 and 2012
30. Certified in NovoTTF-100A alternating electric current delivery system used to treat
recurrent glioblastomas through placement of transducer arrays directly on a patients skull.
Established the first and only ‘clinical center of excellence’ for NovoTTF-100A system
in central and southern Illinois and one of only ~40 centers nationwide
(http://www.novottftherapy.com/patients-centers.php)
HONORS & DISTINCTIONS:
1. Named “Medical Innovator” for 2013 by the Sangamon County Medical Society and
the Springfield Mayor for “Innovations in the treatment of brain and spinal cord tumors”. Honored in an award ceremony by the Mayor of Springfield, Mike Houston on March 7, 2013.
Page 9 of 31
2. Awarded Chief Residency in Neurology - University of Missouri - Columbia (2005-2006)
3. Travel Fellowship from the American Neurological Association (nation-wide
competition) to attend ANA meeting in Toronto, ON, Canada; Funding: $500.00, October 2-6, 2004
4. Scored in the top 1% in North America in the Neurology Residency In-Service Training
Exam (RITE), American Academy of Neurology, 2003 and 2004
5. Selected as one of the top 150 internationally-trained physicians in the Ontario IMG
Program Entrance Exam, University of Toronto, December, 2001
6. Travel Award from the University of Ottawa, Faculty of Graduate and Post-Doctoral Studies to present poster at the Society for Neuroscience, 31st annual meeting, San Diego, Ca, November, 2001
7. Prize for Outstanding Achievements, Ottawa Hospital Foundation, Ottawa, Canada,
November, 2000
8. Post-Doctoral Fellowship Award, Canadian Institutes of Health Research (CIHR) under
the Canadian Neurotrauma Research Program (CNRP); Ranked: 6th nationwide, June, 2000; Title of Project: Rapid Tissue Remodeling in Dentate Gyrus of Adult Rat
Hippocampus Following Excitotoxic Injury. Funding: $120,000; Fellowship Director: Bin Hu, MD, PhD
9. Excellence Scholarship in Science and Engineering (PhD), University of Ottawa, Faculty of Graduate and Post-Doctoral Studies; Funding: $15,000, June, 2000
10. Graduate Admission Scholarship in Science and Engineering (PhD), University of
Ottawa, Faculty of Graduate and Post-Doctoral Studies; Funding: $5,000, January, 2000
11. Travel Award from the University of Ottawa, Faculty of Graduate and Post-Doctoral
Studies to present poster at the Society for Neuroscience, 29th annual meeting, Miami Beach, FL, October, 1999
12. Awarded Medical Degree with Honors, University of Cairo, December, 1992
13. Scholarship of Academic Excellence, University of Cairo, 1987-1992, awarded annually
14. Travel Award from the IFMSA (World Health Organization) to attend Emergency Surgery
Clerkship at University Clinical Hospital, Zaragoza, Spain, 1991
15. Admission Scholarship, University of Cairo, Faculty of Medicine, 1986
Page 10 of 31
16. Admission Scholarship, American University in Cairo, Mechanical Engineering, 1985, declined
MEDIA COVERAGE
Peoria Journal Star. Electric field treatment takes aim at brain cancer. December 26, 2012 http://www.pjstar.com/article/20121226/News/312269854
State Journal Register, Springfield, IL February 13, 2013. Medical innovators to be honored March 7. News about being selected for the medical innovator award.
State Journal Register, Springfield, IL December 3, 2012.. Electric fields extend life for
some brain cancer patients. Read more: http://www.sj-
r.com/article/20121203/News/312039867#ixzz389aJ5V8E
Aspects Magazine. (Featured on Cover). January 19, 2013. Target: Tumors
http://www.siumed.edu/pubs/aspects/36-1/feature1.html
Simmons Cancer Institute Newsletter, Winter 2012. A new standard of care for Glioblastoms. http://www.siumed.edu/cancer/pdf/newsletter/Winter2013.pdf
Brainscan, Fall 2006. Profile Article for the Pencer Brain Trust. http://www.pencerbraintrust.com/downloads/newsletters/brainscan_fall06.pdf
Sangamon County Medical Society July/August 2013 Newsletter. Eleven Medical Professionals
Honored at Medical Innovators Program, Ayman Omar, M.D., Ph.D., SIU School of Medicine, for his novel approaches to treat brain and spinal cord tumors.
http://www.scmsdocs.org Sangamon County Medical Society. Medical Innovators 2013.
http://www.scmsdocs.org/pdf/medinnovators2013.pdf
Page 11 of 31
RESEARCH AND ACADEMIC FUNDING:
• Principal Investigator (authored study design and protocol): Bevacizumab in
combination with alternating electric fields for the treatment of recurrent glioblastoma
NovoCure, Inc., Portsmouth, NH Developer of FDA-approved NovoTTF Technology
Funding: $5000
• Postdoctoral Fellowship Award (National Award)
Canadian Institutes of Health Research (CIHR) Funding: $120,000, June 2000
• Excellence Scholarship in Science and Engineering
University of Ottawa Funding: $15,000, June 2000
• Travel Award (National award competition – 4 selected)
American Neurological Association Attended ANA meeting in Toronto, ON, CANADA
Funding: $500, 2004
• Travel Award to present research findings at Society for Neuroscience, San Diego
Meeting
University of Ottawa Funding: $500, 2001
• Travel Award to present research findings at Society for Neuroscience, Los Angeles
Meeting
University of Ottawa
Funding: $500, 1999
• Graduate Admission Scholarship in Science and Engineering (PhD)
University of Ottawa
Funding: $5,000, January, 2000
• Travel Award to attend Emergency Surgery Clerkship at University Clinical Hospital,
Zaragoza, Spain, 1991
World Health Organization (IFMSA) Funding: Full room and board for 1 month.
Page 12 of 31
. Scholarship for Academic Excellence University of Cairo
Funding: Monthly Stipend, 1987-1992 (award renewed annually)
• University of Cairo Admission Scholarship
Funding: Monthly Stipend, 1986-1987
• American University in Cairo Admission Scholarship, Mechanical Engineering Funding: University Tuition Fees, 1985 (Declined in favor of Medical School)
Page 13 of 31
RESEARCH:
Basic Science Research
07/2000 – 7/2002 CIHR (MRC) Fellow Canadian Institutes of Health Research
Ottawa Health Research Institute, Ottawa Hospital University of Ottawa
Division of Neurosciences Successfully competed and obtained funding (~$120,000) from the premier national research
funding agency in Canada, the Canadian Institutes of Health Research (formerly the Medical Research Council of Canada). My grant proposal was ranked 6th nationwide.
My project focused on investigating the molecular mechanisms governing stem cell proliferation and differentiation in the dentate gyrus of rats following traumatic and ischemic cell injury. I was
able to show for the first time that sodium-potassium pump inhibition up-regulates proliferative activity of stem cells in the subgranular zone of the dentate gyrus. I also showed that in the early
stages post-injury, precursor cells undergo an accelerated rate of migration towards areas of cell injury. These findings may have important functional implications in neural network reconstruction following brain damage. Techniques used in this project include
electrophysiological recordings from acute brain slices, immunofluorescence, in situ hybridization, confocal imaging, digital image analysis and stereotactic CNS micro-infusions.
07/1997 - 07/2000 Research Assistant and PhD Student University of Ottawa
Loeb Health Research Institute, Ottawa Hospital Division of Neurosciences
My research focused on elucidating the mechanisms of ischemic neuronal injury. I was successful in developing a novel in-vivo model for acute ischemic stroke which involved the
stereotactic infusion of ouabain (a sodium-potassium ATPase pump blocker) with fluorescent molecular probes into the dentate gyrus of adult rats. This model allowed for the delineation of the cellular and molecular responses of neurons to ischemic injury, and allowed the visualization
of lipid bilayer and DNA conformational changes post-injury. I subsequently utilized this model to study the mechanisms of mannitol-based neuroprotection particularly its effects on sodium
and potassium ion regulation in neurons.
Page 14 of 31
Clinical Research (Selected trials as PI or co-investigator)
Glioblastoma Multiforme
• Avastin and Temozolomide following Radiation and Chemotherapy for Newly Diagnosed
Glioblastoma Multiforme: A Phase II Study
Avastin, a monoclonal antibody angiogenesis inhibitor is added to the standard of care treatment of temozolomide chemotherapy to determine the safety and effectiveness of the combination. Patients may receive treatment until progression or unacceptable toxicities.
• Avastin , Temozolomide, Bevacizumab and RT followed by Temozolomide and Avastin
versus Avastin and Temodar vs. RT/TMZ + placebo followed by TMZ plus placebo for
newly diagnosed GBM: International, muticenter, randomized, double blinded placebo
controlled trial (AVAGLIO)
Study name: AvaGlio (Avstin in Glioblastoma). This is an International phase III trial (the largest trial of its kind for the treatment of Glioblastoma (GBM), the most aggressive brain cancer) examining the efficacy of adding Avastin (a drug that chokes off blood supply to brain cancer) to
standard tx. for newly diagnosed GBM patients. Attended European Investigator meeting in Vienna, Austria (June 15-18, 2009) representing Northshore University HealthSystem, USA as
one of the US study sites that participated in this international trial (one of 143 centers worldwide). In Vienna, I was able to point out a critical problem with the study design that was previously overlooked by the international study team and as a result an amendment was
resubmitted to the FDA for approval
• A Phase II Study of CDX-110 with Radiation and Temozolomide in Patients with Newly
Diagnosed Glioblastoma Multiforme: Phase II/III
CDX110 is a vaccine which recognizes the protein EGFRvIII in GBM. The purpose is to
determine effectiveness and side effects of adding CDX-110 to the standard of care treatment for GBM. Patients will receive Temodar days 1-5 of a 28-day cycle and the CDX-110 vaccine on day 21 of each cycle. Treatment may continue with Temodar for up to one year and the vaccine
continues until progression or unacceptable toxicities.
• Temozolomide Alone and in Combination with Possible Permutations of Thalidomide,
Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy for Glioblastoma
Multiform
The purpose of this study is to compare treatment of temozolomide with the combination and the above mentioned drug to determine the efficacy and safety of these combinations.
Page 15 of 31
. A Phase I Study of Temozolomide and RAD001C in Patients With Malignant
Glioblastoma Multiforme, Sponsor: National Cancer Institute of Canada
Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the tumor. Giving temozolomide together with everolimus may kill more tumor cells.
This phase I trial is studying the side effects and best dose of everolimus when given together
with temozolomide in treating patients with newly diagnosed, recurrent, or progressive malignant glioblastoma multiforme.
• Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma,
Sponsor: Eli Lilly and Company
This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).
• The Temozolomide RESCUE STUDY: A Phase II Trial of Continuous (28/28) Dose-
Intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28
Day Temozolomide in Patients With Recurrent Malignant Glioma, Sponsor: Schering-
Plough, Schering Canada, Inc.
The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense
temozolomide (50 mg/m2) for up to 12 months may overcome resistance and be effective in the management of adult patients with malignant glioma who have failed following at least 2 cycles (2 months) of conventional 5-day (5/28) cycles of high-dose temozolomide (150-200 mg/m2).
Recurrent Glioblastoma Multiforme
• Ayman Omar, MD, Principal Investigator. NovoTTF100A in combination with
Bevacizumab for the treatment of recurrent glioblastoma. Grant for $5000 from
NovoCure. May 2013.
This project involves developing a novel treatment approach for the treatment of
recurrent GBM patients. The method involves combining the NovoTTF-100A system which delivers alternating electric fields to the brain tumor with bevacizumab, a VEGF inhibitor.
• Phase III, Randomized, Parallel Group, Multicenter Study in Recurrent Glioblastoma
Patients to Compare the Efficacy of Cediranib (Recentin, AZD2171) Monotherapy and
the Combination of Cediranib with Lomustine to the Efficacy of Lomustine Alone
Cediranib is a highly potent and selective VEGF signaling inhibitor that targets all three VEGF
Page 16 of 31
receptors.2 VEGF signaling is a key driver of angiogenesis - the formation of new blood vessels that tumors need to grow and spread.
Low Grade Gliomas • Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low
Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study, Sponsor:
European Organization for Research and Treatment of Cancer and the National Cancer
Institute of Canada.
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective than temozolomide in treating gliomas.
This randomized phase III trial is studying radiation therapy to see how well it works compared to temozolomide in treating patients with gliomas.
Metastatic Brain Cancer
• Evaluating the Treatment Effects of Surgery plus GLIADEL Wafer in Patients with
Metastatic Brain Cancer
The purpose of this study is to find out the effects of surgery and the placement of Gliadel wafers
on the neurocognitive function of patients with metastatic brain cancer. NeuroOphthalmology Research
• Role of tetracycline in the treatment of chronic progressive external ophthalmoplegia
(CPEO)". Principal Investigator: Lenworth Johnson, Professor of Ophthalmology
(Neuro-Ophthalmology) and Neurology, University of Missouri - Columbia. Co-
Investigator: A.I. Omar, Neurology Chief Resident, University of Missouri - Columbia.
University of Missouri IRB Project #: 1059518. (1/06/ - 7/06)
This is a retrospective analysis of the effect of tetracycline antibiotics on ocular motility in chronic progressive external ophthalmoplegia. CPEO is a hereditary mitochondrial myopathy that results in progressive weakness of the extraocular muscles involved in eye movement.
Patients with CPEO have limited eye movements which can result in double vision, difficulty with reading and gait disturbance. These symptoms are chronic and progressive, as the name
implies, and can be debilitating for patients affected by this condition. To date, there are no available effective treatment options for this disease. Some of our patients have been treated with tetracycline and have had apparent improvement in eye movement. After retrospectively
analyzing the data, we have shown for the first time that tetracycline can play a role in improving ocular motility and in delaying progression of the disease.
Page 17 of 31
TEACHING EXPERIENCE: Southern Illinois University School of Medicine
June 2010 - Present
Author of senior clinical competency exam case, “Intracranial hypotension secondary to a spinal CSF leak”, July 2013. This case is part of the 4th year medical student clinical competency assessment.
Headache lecture to family practice residents 5/8/13
MS lecture to Internal Medicine Residents on 5/20/13
Resident teaching on the inpatient service
Resident clinic supervision. Teaching of Neuroscience course for Neurology Residents
Medical Student teaching: CNS tumors lecture
Medical student teaching on inpatient and outpatient services
Resident supervision during Journal Clubs Examiner: Resident NEX exams (American Board of Psychiatry and Neurology)
Director of Neurological Oncology resident elective rotation
Director of NeuroImmunology and Multiple Sclerosis resident elective rotation
NeuroOncology: The Essentials, 5 1-hr lectures from March 19-23, 2012 to Neurology residents
Lectures on Multiple Sclerosis to Neurology residents February 21, 2012 Lectures on Neurologic complications of HIV to Neurology residents, May 2012
Lectures on evaluation and management of pituitary tumors to Neurology Residents at SIU, May
2012
Page 18 of 31
University of Chicago July 1, 2009 – March 31, 2010
Teaching Medical Residents and Medical students on in- and outpatient services
Northwestern University, Feinberg School of Medicine
August 1, 2008 – June 30, 2009
Resident, medical student and physician assistants teaching /supervision on medical wards as well as classroom lectures, bedside demonstrations and supervision of patient related procedures.
University of Toronto, Faculty of Medicine
July 1, 2006 – June 30, 2008 Supervised residents as Fellow in Neurological Oncology
Supervised a medical student from Germany for 1 month as part of a University of Toronto
international medical student exchange program
University of Missouri - Columbia July 1, 2002 – June 30, 2006
Taught medical students as floor and consulting Neurology Resident.
Taught Introduction to Physical Diagnosis and Advanced Physical Diagnosis (APD) to 1st and 2nd year medical students
CSF Dynamics and Intracranial Pressure course, February 2, 2006, Posted online WebCT, University of Missouri – Columbia
University of Ottawa, Faculty of Medicine January, 1998 – June, 2002
Teaching Assistant: Neurology Block (MED2104; Course Director: Prof. W. Hendelman, 01/1999 - 02/2000)
This position involved teaching the "Neurology block" to 2nd year medical students which included theoretical Neuroanatomy, Neurology, and Neuroradiology case studies as well as cadaver specimens and laboratory demonstrations.
Supervised medical students and lab trainees in Neuroscience research techniques including
immunofluorescence, tissue processing, stereotactic brain infusions, confocal microscopy techniques (Laboratory of Bin Hu, MD, PhD).
Page 19 of 31
CME (selected)
04/29/2009 Annual Meeting - 5PC.005: Neurodevelopmental Disabilities Across the Lifespan 3.50
04/08/2006 Annual Meeting - 8AC.007: Therapeutic Poisoning: Immunosuppressive Therapy for
Non- 3.50 04/07/2006 Annual Meeting - 7SC.001: Future of Neuroscience Conference: Stem Cells and
Neurological diseases 7.50 04/06/2006 Annual Meeting - 6BS.002: Neuro-oncology Update 1.50
04/05/2006 Annual Meeting - 5PC.004: Diagnosis, Management, and Rehabilitation of Traumatic Brain Injury 3.50
04/09/2005 Annual Meeting - 5CS.001 Multiple Sclerosis and Related Disorders: A Case-Based
Approach 3.00 04/09/2005 Annual Meeting - 6CS.003 Unusual Diagnostic and Management Problems in
Neuromuscular Disorders 3.00 04/09/2005 Annual Meeting - 6PC.002 Neurological Complications of Medical Disease 3.50
04/09/2005 Annual Meeting - 7FC.001 Genetics in Neurology 6.50
04/09/2005 Annual Meeting - 8AC.004 Structure Function Correlations in Behavioral Neurology 3.50
6/16/2012 Improving the Frontline Management of Multiple Sclerosis: Case Studies for the
Practicing Clinician – Med-IQ Obtained 30 credits through maintenance of certification program of the Royal College of
Physicians and Surgeons of Canada – 15th International Symposium on Pediatric NeuroOncology – Toronto, Canada – June 24-27, 2012
Update on NovoTTFTM Therapy Efficacy and Safety for Recurrent GBM: Commercial Registry Data" on Wednesday, May 21, 2014, Webinar presented by Eilon Kirson, MD, PhD, Head of
R&D and Chief Science Officer, Novocure, Inc.
Page 20 of 31
PROFESSIONAL AFFILIATIONS:
. American Academy of Neurology, Section of NeuroOncology, member since 2009
· American Academy of Neurology (AAN), member since 2003 (Active) . Society for NeuroOncology (SNO), USA, member since 2008
. College of Physicians and Surgeons of Ontario (CPSO), Canada (member 2006 - 2008)
· Society for Neuroscience (SFN), USA: member since 2000 (Inactive)
· American Physiological Society (major affiliation with CNS section): member since 1999 (Inactive)
· Egyptian Medical Syndicate (Fully Licensed Physician), Egypt: member since 1996
OTHER ACADEMIC ACTIVITIES:
. Consulting Member of Advisory Board, Novocure Ltd., Portsmouth, NH, Development of NovoTTF-100A technology for the management of Glioblastoma, December 7, 2013 –
December 6, 2014
. Member of Advisory Board, EMD Serono. Current management of glioblastoma multiforme in the community practice setting, May 14, 2013.
EDITORIAL BOARD AND JOURNAL REVIEWER
. Associate Editor, Journal of Neurology and Neurosurgery - Open Access, June 2016 - Present
. Reviewer, Journal of Spine, September, 2013 – Present
. Reviewer, Journal of Visualized Experiments, November 2014 – Present
. Reviewer, Journal of Vascular Medicine and Surgery, November 2014 - Present . Reviewer, Journal of Gastrointestinal Diseases, April 2016 - Present
Page 21 of 31
LANGUAGES AND TRAVEL:
Fluent: English and Arabic. Knowledge of: French, Serbian, Romanian and Persian.
Lived and visited the following countries either for education, business, or pleasure: China, Japan, Mongolia, Iran, India, Pakistan, Kuwait, Jordan, Egypt, Morocco, Sweden, Finland, Denmark, Norway, Germany, Austria, Netherlands, Belgium, Luxembourg, France, England,
Bulgaria, Romania, Yugoslavia, Spain, Greece, Italy, Canada, and the United States.
COMPUTER SKILLS:
OS Platforms: Windows 95/98, ME, MS Dos, MacOs, NT. Applications: Wordprocessing Software (MS Word, WordPerfect), Statistical Analysis Software
(Excel, Sigma Plot), Image Acquisition and Analysis (NIH Image, Northern Eclipse, etc.), Image Processing, Computer Graphics and Animation (Adobe Photoshop, Corel Photopaint/Corel Draw
etc.), Presentation (Power Point). Internet: Professional Medline Searches, Netscape, Explorer. Web Page Design: HyperText Markup Language (HTML), Java Script Programming, C++
Programming (Created software for diagnosing fetal distress in high risk pregnancies; copyrighted
CLINICAL PROCEDURAL SKILLS:
Mastered various procedural skills including: Internal Medicine Skils:
Thoracentesis, paracentesis, arthrocentesis, bone marrow biopsies, phlebotomy, peripheral IV
line access, femoral central lines, EKG hookup and interpretation, advanced airway management including intubation as well as various ACLS skills (advanced airway management, rhythm interpretation and ACLS management, operating AEDs and manual defibrillators, synchronized
cardioversion, transcutaneous pacing, management of Acute Coronary Syndromes and stroke per AHA guidelines, etc.). ATLS skills: chest tube insertions and evaluation and management of
various traumas including head traumas.
Page 22 of 31
Basic Surgical Skills:
Including suturing and wound closure, abscess drainage etc., also assisted in some neurosurgical procedures during a 2 month Neurosurgery internship rotation including VP shunt and
ventriculostomy placement as well as some craniotomies for evacuation of epidural hematomas etc.
Neurology Skills:
Lumbar punctures (over 1000 procedures to date), Baclofen intrathecal infusions as part of trial for Baclofen pump surgery, Tensilon tests, EEG and sleep studies interpretation, performing and
interpreting nerve conduction studies as well as EMG of extremities and paraspinal muscles. Excellent skills in neuroimaging interpretation (CTs, MRI/MRA head and neck etc.). Use of
immunomodulatory agents including interferons, Gilenya and Tysabri infusions (registered physician through the FDA mandated TOUCH program), occipital nerve blocks, evaluation and management of acute strokes, intracranial hemorrhage, critical care neurology, etc..
Completed an intensive 1 month training in Critical Care/Intensive Care Neurology at Barnes
Jewish Hospital, Washington University in St. Louis, October 2005 (Barnes Jewish is ranked as one of the top 10 hospitals in the United States). Patients managed included gunshot wounds to the head, ruptured cerebral aneurysms, Traumatic brain injury, Brain abscesses, intracranial
bleeds, patients requiring emergency neurosurgical interventions, pre and post-procedure care for patients undergoing neurendovascular procedures such as cerebral angioplasty/ stenting and
coiling of intracranial aneurysms, etc.
NeuroOncology Skills:
Extensive knowledge of chemotherapeutic agents, their methods of administration, potential toxicities and their management
Management of neurologic complications related to systemic cancer
Diagnosis and management of Primary Brain Tumors (over 120 different subtypes)
Special expertise in the management of Primary CNS Lymphomas
Knowledge of radiation therapy utilization for the treatment of brain and spinal cord cancers including Whole Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery as well as Intensity Modulated Radiation Therapy (IMRT) for the treatment of brain cancer adjacent to
critical brain structures.
Extensive knowledge of chemotherapy, radiotherapy and immunotherapy for the treatment of primary central nervous system lymphomas including the use of monoclonal antibodies that
Page 23 of 31
target molecules specific to cancer cells.
Extensive knowledge in the treatment of leptomeningeal metastatases (spread of systemic cancer to the brain coverings as well as the cerebrospinal fluid) including the use of Ommaya reservoirs
intraventricular chemotherapy infusion. Recognized as an expert in the treatment of leptomeningeal cancer (co-authored a book chapter in the leading international Cancer Neurology reference textbook, Cancer Neurology in Clinical Practice.
Developed a “Brain Metastases Clinic” at the NorthShore University HealthSytem, the first
Brain Metastases Clinic in the State of Illinois. Certified as a “clinical center of excellence” provider of a novel brain cancer treatment technique
involving the delivery of electromagnetic waves using electrode arrays placed on patients skull using NovoTTF-100a device. This is an FDA approved treatment. I’m currently the only
provider of this technology in central and southern Illinois and one of approximately 40 centers nationwide. http://www.novottftherapy.com/patients-centers.php
Neuroimmunology Skills: Directed SIU Multiple Sclerosis clinic (2011-2013)
Extensive knowledge in treatment of demyelinating diseases such as multiple sclerosis
Knowledge in use of Tysabri infusions, use of interferons, Gilenya, chemotherapeutic agents for the treatment of MS, etc.
University Boards and Committees
• Member and Reviewer, Springfield Committee on Research Involving Human Subjects (SCRIHS IRB): Role is to review clinical research proposals in the Springfield area and ensure they meet local, institutional and FDA and international guidelines (June 2010 – July 2013)
• Member, Senior Clinical Competency Committee (CCX Curriculum Committee), Southern
Illinois University School of Medicine. Role is to develop clinical competency exams for senior graduating medical students.
• Developed Neurological Oncology Tumor Board (first in Southern Illinois University): Currently moderating a bimonthly board meeting comprised of Neurosurgeons, Radiation
Oncologists, Medical Oncologists, Neuroradiologists, Neuropathologists and myself as Neurological Oncologist and Tumor Board moderator. This tumor board is approved for AMA CME credits (June 2010 – Present).
Page 24 of 31
• Member, Simmons Cancer Institute: Operating and directing a Neurological Oncology service
at SCI (July 2010 – July 2013).
• Member, Data Safety Monitoring Board for Evaluation of 5-alpha levulinic acid as an intraoperative fluorescent marker during glioma surgery, PI: Jeffrey Cozzens, MD
PUBLICATIONS:
Page 25 of 31
Peer-Reviewed Journal Articles:
1. A. I. Omar, Tumor Treating Field Therapy in Combination with Bevacizumab for the
Treatment of Recurrent Glioblastoma. J. Vis. Exp. (92), e51638, doi:10.3791/51638 (2014). http://www.jove.com/video/51638/tumor-treating-field-therapy-combination-with-bevacizumab-for
2. A. I. Omar, Holmes-Adie Syndrome in the Setting of Induced Hypothermia is Associated
with Delayed Recovery from General Anesthesia. Open Access J Neurol Neurosurg. 2016; 1(2): 555558.
3. A.I. Omar. Molecular pathways in malignant gliomas: Targets for rational anticancer drug design (In Preparation)
4. A.I. Omar, J. Cozzens, B. Moore. Molecular characterization and response to treatment
of a primary CNS lymphoma (In Submission)
5. A.I. Omar. Complicated migraine with complex regional pain syndrome after
craniospinal irradiation for medulloblastoma: A possible SMART variant. (In Submission)
6. Ayman I. Omar, Pankaj Jalan, Vijay Pandav, Simon Bekker. Extensive venous sinus thrombosis in a patient with sinonasal undifferentiated carcinoma with a dural-based
metastasis. (In Submission)
7. P. Jalan, P Bhargava, Asa and A.I. Omar. Successful treatment of dermato-neuro
syndrome associated with scleromyxedema with intravenous immunoglobulin: A proposed mechanism of action (– In review)
8. P. Jalan, V. Pandav, L. Dhakkal, A. Omar. Status migrainosus as a potential stressor
leading to Takutsubo cardiomyopathy. Cephalalgia, 2012 Nov;32(15):1140-3. Epub 2012
Sep 18.
9. A.I. Omar. Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma. Journal of Medical Case Reports 2012, 6:238. (Received Highly Accessed designation by BioMed Central – A designation given to highly accessed
articles relative to their age and journal in which they were published) Article also chosen by MDLinx (www.MDLinx.com) for a news feed informing
clinicians of important developments in the surgical field
10. A.I. Omar and W.P. Mason. Temozolomide: The evidence for its therapeutic efficacy in
malignant astrocytomas, Core Evidence 2009:4 93–111
11. A.I. Omar, L.N. Johnson. Tetracycline delays ocular motility decline in chronic progressive external ophthalmoplegia. (Neurology, 2007; 68: 1159)
Page 26 of 31
12. Mooney DM, Zhang L, Basile C, Senatorov VV, Ngsee J, Omar AI, Hu B.. Distinct forms
of cholinergic modulation in parallel thalamic sensory pathways. Proc. Natl. Acad. Sci. U S A. 2004 Jan 6;101(1):320-4. Epub 2003 Dec 22. (Chosen by Faculty of 1000 as one of
the most important scientific articles in Neuroscience - Sherman S: 2004. F1000.com/1016818#eval201453)
13. A.I. Omar and B. Hu. Detection of early tissue injury in vivo using fluorescent cell death markers in rat dentate gyrus. Neurosci Lett. 2003 Sep 18;348(3):143-6.
14. A.I. Omar, V.V. Senatorov, and B. Hu. Sodium-potassium adenosine triphosphatase
inhibition enhances membrane accumulation of DiI in rat hippocampus in vivo.
Neuroscience 102 (2), 353-359. (2001)
15. A.I. Omar, V.V. Senatorov, and B. Hu. Ethidium bromide staining reveals rapid cell dispersion in the rat dentate gyrus following ouabain-induced injury. Neuroscience 95 (1), 73-80. (2000)
PHD DISSERTATION
1. A.I. Omar. Tissue injury and remodeling in rat hippocampal dentate gyrus following Na+,
K+, ATPase Inhibition. PhD Dissertation, University of Ottawa, Faculty of Medicine, Dissertation Abstracts International and the National Library of Canada, (Advisor: Bin
Hu, MD, PhD) (©2002). Dissertation Nominated by Reviewers for University Award.
MASTERS THESIS
1. A. I. Omar, Endovascular NeuroOncology: A new frontier for the management of brain and spinal cord malignancies, University of Oxford, MSc. In Endovascular Neurosurgery, 2016
2. A. I. Omar, Endovascular Neurosurgery Operative Techniques: Logbook of Cases,
University of Oxford, Interventional Neuroradiology, 2016
Book Chapters and Reviews:
1. A.I. Omar and W.P. Mason. Anaplastic astrocytomas – Neurooncology (M.J. Aminoff, F.
Boller and D.F. Swaab, eds.), Elsevier Press, Handbook of Clinical Neurology, 2012;105:
451-66.
2. A.I. Omar and W.P. Mason. Leptomeningeal Metastases in Cancer Neurology in Clinical
Page 27 of 31
Practice (David Schiff, MD, Patrick Y. Wen, MD and Santosh Kesari,MD, PhD, eds.), Humana Press Inc., Totowa, NJ., (© 2007)
3. A.I. Omar and W.P. Mason. Glial Tumors: Low-grade and anaplastic oligodendrogliomas, International Neurology (M. Rosenfeld, MD and J. Dalmau, MD, eds.)
4. A.I. Omar and W.P. Mason. The Molecular Basis For The Genesis Of Malignant Gliomas: Targets For Novel Anti-Cancer Therapeutics. Oncology Rounds (2006)
Abstracts:
1. Ayman I Omar. Targeting the vascular endothelial growthfactor pathway for the treatment
of surgically unresectable spinal cord hemangioblastomas. Submitted to the American Academy of Neurology meeting in San Diego, March 16-23, 2013.
2. Ayman I. Omar, Pankaj Jalan, Vijay Pandav, Simon Bekker. Extensive venous sinus thrombosis in a patient with sinonasal undifferentiated carcinoma with a dural-based
metastasis. Society for NeurOncology 2012 annual meeting, Nov. 15-18, Washington, DC (Pesented poster abstract to be published in NeuroOncology, the official SNO journal)
3. A.I. Omar. Complicated migraine with complex regional pain syndrome after
craniospinal irradiation for medulloblastoma: A possible SMART variant. (Neuro Oncol (2012) 14 (suppl 1): i125-i139: Abstracts from the 15th International Symposium on Pediatric Neuro-Oncology, June 24-27 2012 Toronto, Ontario, Canada)
4. A.I. Omar. Bevacizumab for the treatment of surgically unresectable cervical cord
hemangioblastoma. Neuro Oncol (2011) 13 (suppl 3):iii41- iii68, Abstract presented at the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the American Association of Neurological Surgeons/CNS Section on Tumors,
Orange County, California, November 17-20, 2011
5. M. K. Nicholas, R. V. Lucas, J. Arzbaecher, N. Paleologos, H. Krouwer, M. Malkin, A.I. Omar, N. A. Vick. Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II
study. J Clin Oncol 27:15s, 2009 (suppl; abstr 2016)
6. A.I. Omar and L.N. Johnson. Tetracycline delays the decline in ocular motility in chronic progressive external ophthalmoplegia. (16th International Neuro-ophthalmology Society (INOS) Congress 2006, Neuro-opthalmology, Volume 30, Number 6, 2006)
7. A.I. Omar, C. Basile, J. Ngsee, D. Mooney, and B. Hu. Differential expression of m1 and m2 muscarinic receptors in rat leminiscal and non-lemniscal medial geniculate body. Soc.
Page 28 of 31
Neurosci. Abstr. Vol. 28, Orlando, FL. (November 2002)
8. A.I. Omar and B. Hu. Monitoring DNA condensation in vivo using the DNA fluorescent probe Hoechst 33342 following ouabain-induced injury. Soc. Neurosci. Abstr. Vol. 27,
San Diego, CA. (November 2001)
9. A.I. Omar and B. Hu. Intrahippocampal ouabain infusion upregulates proliferatvie
activity of the subventricular zone progenitor cell population. Soc. Neurosci. Abstr. Vol. 26, Part I, p. 286. Presented at the Society For Neuroscience 30th annual meeting, New
Orleans, LA. (November 4-9, 2000)
10. A.I. Omar and B. Hu. Evidence for a lesion-induced accelerated migration of newly born
precursor cells in adult rat dentate gyrus. EB 2000 Abstr. Add. Presented at the "Experimental Biology 2000" Conference, San Diego, CA. (April 2000)
11. A.I. Omar, V.V. Senatorov, and B. Hu. Enhanced membrane uptake of a lipophilic
fluorescent probe following intrahippocampal ouabain administraion: A possible in vivo
marker for membrane damage. Soc. Neurosci. Abstr. Vol. 25, Part I, p. 995. Presented at the Society for Neuroscience 29th annual meeting, Miami Beach, FL. (October 23-28,
1999)
12. A.I. Omar, V.V. Senatorov, M. Tiberi, and B. Hu. Rapid induction of granule cell
dispersion in the dentate gyrus of the adult rat hippocampal formation by ouabain. Soc. Neurosci. Abstr. Vol. 24, Part I, p. 718. Presented at the Society for Neuroscience 28th
annual meeting, Los Angeles, CA. (November 7-12, 1998)
Presentations:
1. A.I. Omar. Cerebral arterial anatomy, University of Oxford Tutorials, October 2014
2. A.I. Omar. Cerebral venous anatomy, University of Oxford Tutorials, October 2014
3. A.I. Omar. Control of cerebral blood flow, University of Oxford Tutorials, November 2014
4. A.I. Omar. Dangerous extracranial to intracranial anasomoses, University of Oxford
Tutorials, November 2014
5. A.I. Omar, E. Karroum and B. Moore. Sellar Masses. Clinical Pathology Conference
(Grand Rounds). 2013
Page 29 of 31
6. Melikyan and A.I. Omar. Journal Club. SIU School of Medicine 2/18/2013. Antoniol
C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by
corticotherapy: effect on PML-IRIS management? Neurology. 2012 Dec 4;79(23):2258-
64
7. A.I. Omar and Suzanna Johnston. Management of Recurrent Glioblastomas with
Electromagnetic Tumor Treating Fields: A Novel Treatment with NovoTTF-100A Device.
Neurology and Neurosurgery Grand Rounds. Southern Illinois University School of
Medicine. January 29. 2012
8. A.I. Omar. Examination of the Comatose Patient. Lecture presented to second year
medical students. SIU School of Medicine, January 24, 2013
9. A.I. Omar, S. Dandapat and B. Moore. Meningioma mimics. Clinical Pathology
Conference (Grand Rounds). December 4, 2012
10. A.I. Omar and L. Dhakal. Inflammatory Demyelinating Brain Lesions Heralding Primary CNS Lymphoma. Grand Rounds (Journal Club). May 15. 2012
11. A.I. Omar and L. Dhakal. Clinical Pathology Conference (Grand Rounds). March 6,
2012, The Road from PhD to Dementia: Alzheimers with posterior cortical atrophy admixed with diffuse Lewy body disease pathology. Southern Illinois University School of Medicine.
12. A.I. Omar. Clinical Pathology Conference (Grand Rounds). January 3, 2012, 20 year old
with intractable seizures: Ganglioglioma intermixed with an arteriovenous malformation – Angioglioma? Southern Illinois University School of Medicine.
13. A.I. Omar. Advances in the management of brain metastases. Neurology and Neurosurgery Grand Rounds, November, 2011, Southern Illinois University School of
Medicine.
14. A.I. Omar. Bevacizumab for the treatment of surgically unresectable cervical cord
hemangioblastoma: A novel approach. Neurology and Neurosurgery Grand Rounds, June 2011, Southern Illinois University School of Medicine.
15. A.I. Omar. Current Management Strategies for Malignant Astrocytomas. Neurology and
Neurosurgery Grand Rounds, April 25, 2011, Southern Illinois University School of
Medicine.
16. V Sabodash and A.I. Omar. Grand Rounds (Journal Club). Transcranial Magnetic Stimulation. March 2011, Southern Illinois University School of Medicine.
Page 30 of 31
17. A.I. Omar. Clinical Pathology Conference (Grand Rounds). April, 2011, Unusual presentation for an intraventricular mass lesion. Southern Illinois University School of
Medicine.
18. A.I. Omar. Rapid Onset of Obstructive Hydrocephalus and Seizures in an Otherwise Healthy Female Patient. 10/6/2008. Clinical Neurosciences conference, NorthShore University HealthSystem and Northwestern University Feinberg School of Medicine
19. A.I. Omar. Brain metastases: The current state of knowledge. 12/11/08. Medicine Grand
Rounds, NorthShore University HealthSystem and Northwestern University Feinberg School of Medicine
20. A.I. Omar. Neuro-HIV. 3/21/09, Clinical Neurosciences conference, NorthShore University HealthSystem and Northwestern University Feinberg School of Medicine
21. A.I. Omar. Molecular approaches for the treatment of malignant astrocytomas: From the
bench to the bedside. Neurology/Neurosurgery Grand Rounds. University of Missouri -
Columbia (April 26, 2006)
22. A.I. Omar. New-onset seizures in a young female: A diagnostic challenge. Neurology/Neurosurgery Grand Rounds. University of Missouri - Columbia (November 23, 2005)
23. A.I. Omar. Guidelines for the management of the severely head-injured patient.
Neurology/Neurosurgery Grand Rounds. University of Missouri - Columbia (October 6, 2004)
24. A.I. Omar. Critical care strategies in traumatic brain injury. Invited speaker at the Division of Pulmonary and Critical Care Medicine. University of Missouri - Columbia.
(October 19, 2004)
25. A.I. Omar. Injury induced remodeling in the Central Nervous System. Neurology/
Neurosurgery Grand Rounds, University of Missouri, Columbia, Missouri. (April, 2004)
26. A.I. Omar and B. Hu. Local and distant tissue remodeling in rat hippocampus following ouabain-induced injury. Presented at the University of Ottawa, Cellular and Molecular Medicine Seminars. (April 18, 2001)
27. A.I. Omar and B. Hu. Early tissue reactive changes following sodium-potassium
adenosine triphosphatase pump inhibition in the adult rat dentate gyrus. Presented at the University of Ottawa, Cellular and Molecular Medicine Seminars. (November 2000)
28. A.I. Omar. Journal Club Presentation: Presented at the "Neurotalks" meeting at the Loeb Health Research Institute, Ottawa, Canada. (October 5, 2000) Prenatal stress produces
learning deficits associated with an inhibition of neurogenesis in the hippocampus. V. Lemaire et al. Proc. Natl. Acad. Sci. USA, Vol. 97, Issue 20, 11032-11037. (2000)
Page 31 of 31
29. A.I. Omar and B. Hu. Dynamics of lesion-induced proliferation and cellular
reorganization in the adult rat brain. Presented at the University of Ottawa, Cellular and Molecular Medicine Seminars. (December 1999)
30. A.I. Omar and B. Hu. In vivo cellular and molecular responses to Na+, K+, ATPase Pump
blockade in the rat dentate gyrus. Presented at the University of Ottawa, Faculty of
Medicine seminar series. (April 1999)
31. A.I. Omar, V.V. Senatorov, and B. Hu. Ouabain induces rapid cell dispersion and network remodeling in the adult rat hippocampal formation. Presented at the University of Ottawa, Faculty of Medicine seminar series. (April 1998)